Helicobacter pylori biofilm matrix (H. pylori biofilm matrix)

The Helicobacter pylori biofilm matrix is a complex, self-produced assembly of extracellular polymeric substances (EPS) that encases the bacteria, providing a protective environment within the gastric mucosa (PubMed: 33437154). This matrix is primarily composed of polysaccharides, proteins, lipids, and extracellular DNA (eDNA), which collectively facilitate bacterial adhesion to gastric epithelial cells (PubMed: 26811553). It shields the pathogen from the harsh acidic environment of the stomach and the host's immune response, allowing for long-term colonization (PubMed: 31652813). Crucially, the biofilm matrix acts as a physical and chemical barrier that significantly reduces the penetration and efficacy of conventional antibiotics (PubMed: 33437154). This resistance mechanism contributes to the high rates of treatment failure and chronic persistence of H. pylori infections seen in clinical practice (PubMed: 31652813). Targeting the biofilm matrix, often through the use of mucolytic agents like N-acetylcysteine or bismuth-based compounds, aims to disrupt this protective shield (PubMed: 32824104). By degrading the matrix, these agents sensitize the bacteria to standard antimicrobial therapy, potentially improving eradication rates (PubMed: 25611281). Research into matrix-degrading enzymes and anti-biofilm peptides represents a promising frontier for treating multidrug-resistant H. pylori strains (PubMed: 31652813).

Other names

Extracellular polymeric substancesEPSH. pylori extracellular matrixBiofilm EPSH. pylori biofilm

The mechanism of action involves the physical and chemical degradation of the extracellular polymeric substances (EPS), such as the cleavage of disulfide bonds by N-acetylcysteine or the enzymatic digestion of extracellular DNA by DNase I, which disrupts the biofilm's structural integrity and increases the penetration of co-administered antibiotics.